“MGI Pharma - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by MGI Pharma. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there is “1” cancer drugs in clinical pipeline.
The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.
“MGI Pharma - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.
1. MGI Pharma
1.1 Business Overview
1.2 MGI Pharma Cancer Pipeline Overview
2. MGI Pharma Cancer Drugs in Preclinical Phase
2.1 PARP Inhibitors - Eisai
3. No Development Reported in Cancer Drugs in Clinical Pipeline
3.1 E 7016
3.2 Thyroid Cancer Therapeutics - MGI Pharma
4. Discontinued in Cancer Drugs in Clinical Pipeline
4.1 MG 98
4.2 Paclitaxel - MGI GP
4.5 ZYC 300
4.6 GPI 5693
4.7 DNA Methyltransferase Inhibitors - MGI Pharma
4.8 Monoclonal Antibodies - Medarex/MGI Pharma Biologics
4.9 Cancer Vaccines - MGI Pharma Biologics/sanofi Pasteur
4.10 NAALADase Inhibitors - MGI GP
4.11 Acylfulvene Analogues - MGI Pharma
4.12 Anti-CYP1B1 Antibodies - MGI Pharma Biologics
Figure 1-1: MGI Pharma Cancer Pipeline by Phase (%)
Figure 1-2: MGI Pharma Cancer Pipeline by Phase (Number)